PharmaResearch has officially launched Rejuran in Hungary, widening the South Korean company's footprint across the European aesthetics market.

The launch makes Hungary the newest European market where the injectable is available to clinicians. PharmaResearch has positioned the rollout as part of a deliberate, country-by-country expansion of the brand across the continent.

The announcement itself is brief. The company confirmed the Hungarian launch but released no accompanying data — no injector numbers, no pricing, no distribution partner details, and no pricing or reimbursement specifics for the Hungarian market. That leaves the strategic picture clearer than the commercial one: PharmaResearch is prioritizing geographic breadth in Europe, adding markets as regulatory and distribution pathways allow.

For dermatologists and aesthetic practitioners in Hungary, the significance is straightforward. Rejuran, a polynucleotide-based regenerative injectable, joins the roster of skin-boosting and biostimulatory treatments available in the country. Practitioners evaluating whether to add it to their treatment menus will need to weigh the manufacturer's positioning against whatever published clinical evidence supports the specific formulation being distributed in Hungary — a distinction Derm Field readers know well from previous coverage of the skin-booster category.

What the launch does and does not tell us

The core fact is confirmed: the product is now officially on the Hungarian market under the Rejuran brand name, distributed by PharmaResearch. Everything beyond that — patient demand, clinic uptake, competitive positioning against established hyaluronic-acid skin boosters — remains to be seen.

European expansion in the injectable-aesthetics segment has accelerated over the past several years, with regenerative and biostimulatory products drawing increasing practitioner interest. PharmaResearch's move into Hungary fits that pattern: a company with an established brand in Asia extending into mid-sized European markets where the aesthetics sector is growing.

What the announcement does not include matters for clinicians tracking the evidence base. No clinical trial results, injector training requirements, or product-line details accompanied the launch statement. Derm Field will monitor whether PharmaResearch publishes formulation specifics, training programs, or post-launch market data for Hungary as the rollout proceeds.

For now, the launch stands as a distribution milestone rather than a data event. Hungarian practitioners gain access to another regenerative injectable option; whether it earns a durable place in European treatment algorithms will depend on the evidence and real-world results that follow.